Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Pharmaceutical
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space.
How has the company achieved this — on the R&D and patient access side — and what is the company doing to help the remaining patients? Vertex’s Andrew Wilfin, Senior Country Medical Director, UK and Ireland, took part in a Q&A with The Pharma Letter to reveal all. 7 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product’s safety, effectiveness or quality. 7 January 2025
Pharmaceutical
Sentynl Therapeutics, wholly owned by Zydus Lifesciences, has announced that the US Food and Drug Administration has accepted its New Drug Application for CUTX-101, a potential first treatment for Menkes disease. The application has been granted priority review, with a target action date set for June 30, 2025. 7 January 2025
All news
Pharmaceutical
Japanese drug major Takeda has received US approval for Fruzaqla (fruquintinib), an oral targeted therapy for bowel cancer. 9 November 2023
Pharmaceutical
An Expert View from Cynthia Miller, vice president, medical director of the access experience team, PRECISIONvalue. 8 November 2023
Pharmaceutical
The US Federal Trade Commission (FTC) has challenged more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and other drug products as improperly or inaccurately listed in the Food and Drug Administration’s (FDA) publication of “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.” 8 November 2023
Pharmaceutical
German life sciences major Bayer has confirmed its group outlook for 2023 after posting third-quarter figures that were down against the previous year. 8 November 2023
Pharmaceutical
Danish CNS specialist Lundbeck today released financials, showing that revenue increased by 10% (+9% constant exchange; CER) to 14,934 million kroner ($2,148.8 million) in the first nine months of 2023. 8 November 2023
Pharmaceutical
Privately-held Italian drugmaker Menarini and USA/China-based SciClone Pharmaceuticals have entered into an exclusive sub-licensing agreement to develop and commercialize Orserdu (elacestrant) in China. 8 November 2023
Pharmaceutical
Italian pharma major Recordati saw its shares rise 3.6% to 45.57 euros yesterday, after it released a strong set of financial results for the first-nine months of 2023. 8 November 2023
Pharmaceutical
Life science compliance specialist Model N has announced product enhancements relating to the Inflation Reduction Act. 8 November 2023
Pharmaceutical
Across pharma companies, teams invest so much time and resources in engaging with their key customers, whether it be at congresses or one-on-one meetings with Key Opinion Leaders (KOLs), and have such a plethora of data surrounding these activities and interactions, that recording and making sense of it all—let alone maximizing the value of engagements according to organizational objectives—can seem a near impossible challenge. 7 November 2023
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is not happy. 7 November 2023
Pharmaceutical
Indian drugmakers Lupin and Zydus Lifesciences have entered into a licensing and supply agreement to co-market, saroglitazar Mg for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in India. 7 November 2023
Pharmaceutical
Swiss pharma giant Roche announced the sector's biggest pharma M&A deal in October. 7 November 2023
Pharmaceutical
German pharma major Bayer has revealed it is expanding its Phase III OCEANIC clinical development program for the investigational drug asundexain (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA. 7 November 2023
Pharmaceutical
UK-headquartered specialty pharmaceutical company Advanz Pharma today announced it expands its specialty brands portfolio with the signing of the acquisition of global rights of Androcur (cyproterone acetate) from German pharma major Bayer. 7 November 2023
Pharmaceutical
American biopharma company Vertex Pharmaceuticals has announced strong third quarter financial results and raised its guidance for product revenues in 2023. 7 November 2023
Pharmaceutical
Swedish nephrology company Calliditas Therapeutics has highlighted new analyses from the Phase III NefIgArd study. 7 November 2023
Pharmaceutical
Anastrozole, which has been used for many years as a breast cancer treatment, has today been licensed by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a preventive option – which it is hoped could help prevent around 2,000 cases of breast cancer in England. 7 November 2023
Pharmaceutical
Thomas Cueni, the director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and secretary of the Biopharmaceutical CEO Roundtable (BCR), is set to retire in April 2024. 6 November 2023
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim today announced promising 14-week Phase II data for BI-690517. 6 November 2023
Pharmaceutical
During 2022, investments in research and development in Sweden continued. 6 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze